Desirée Van Oorschot

Author

Also Known As

D. Van Oorschot, D. van Oorschot, Desiree A. M. van Oorschot, Desiree Van Oorschot, Desiree van Oorschot, Desirée A M van Oorschot, Desirée A. M. Van Oorschot, Desirée A. M. van Oorschot, Desirée A.M. van Oorschot, Desirée Van Oorschot

Publications

855

Citations

H-Index

Concepts

All Affiliations

GlaxoSmithKline (Belgium)GlaxoSmithKline (Germany)University of Minnesota Teikyo Heisei University Ithaka Harbors

About

Desirée Van Oorschot is an author at GlaxoSmithKline (Belgium) specializing in vaccine development, epidemiology, and precision vaccinology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	2	2	54
2	Public Health	2	2	54
3	Epidemiology	2	2	54
4	Clinical Epidemiology	2	2	54
5	Health Economics	1	1	38

Desirée Van Oorschot

Publications

532

Citations

H-Index

Page 1

	Year	Citations
The Epidemiology of Herpes Zoster in Immunocompetent, Unvaccinated Adults ≥50 Years Old: Incidence, Complications, Hospitalization, Mortality, and Recurrence Hung Fu Tseng, Katia Bruxvoort, Bradley K. Ackerson, The Journal of Infectious Diseases	2019	96
Cost-effectiveness of an Adjuvanted Recombinant Zoster Vaccine in older adults in the United States Desmond Curran, Brandon J. Patterson, Lijoy Varghese, Vaccine	2018	70
Meta-Regression of Herpes Zoster Incidence Worldwide Desmond Curran, Andrea Callegaro, Kyle Fahrbach, Infectious Diseases and Therapy	2021	59
Assessment of the potential public health impact of Herpes Zoster vaccination in Germany Desmond Curran, Desirée Van Oorschot, Lijoy Varghese, Human Vaccines & Immunotherapeutics	2017	45
Public Health Impact and Cost-Effectiveness of Non-live Adjuvanted Recombinant Zoster Vaccine in Canadian Adults Ashleigh McGirr, Desirée Van Oorschot, Robyn Widenmaier, Applied Health Economics and Health Policy	2019	39
Cost-effectiveness of an adjuvanted recombinant zoster vaccine in older adults in the United States who have been previously vaccinated with zoster vaccine live Desmond Curran, Brandon J. Patterson, Desirée Van Oorschot, Human Vaccines & Immunotherapeutics Zoster Economic AnalysisVaccine HesitancyZoster VaccineUnited StatesZoster Vaccine Live	2019	38
A Cross-Sectional Concept Elicitation Study to Understand the Impact of Herpes Zoster on Patients’ Health-Related Quality of Life Desirée Van Oorschot, Ashleigh McGirr, Philibert Goulet, Infectious Diseases and Therapy	2022	36
Public health impact model estimating the impact of introducing an adjuvanted recombinant zoster vaccine into the UK universal mass vaccination programme Desirée Van Oorschot, Manjit Hunjan, Benjamin Bracke, BMJ Open	2019	22
Long-term efficacy data for the recombinant zoster vaccine: impact on public health and cost effectiveness in Germany Desmond Curran, Desirée Van Oorschot, Sean Matthews, Human Vaccines & Immunotherapeutics	2021	22
The Potential Public Health Impact of Herpes Zoster Vaccination of People Aged ≥ 50 Years in Japan: Results of a Markov Model Analysis Daisuke Watanabe, Akiko Mizukami, Katsiaryna Holl, Dermatology and Therapy	2018	21

Page 1